Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine I 131 tositumomab

Drug Profile

Iodine I 131 tositumomab

Alternative Names: 131-I-anti-B1 antibody; 131-I-tositumomab; Anti-CD20 murine monoclonal antibody-I-131; B1; Bexxar; I-131 anti-B1 antibody; Iodine 131 tositumomab; Iodine-131 anti-B1 antibody; Tositumomab; TST/I131-TST

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corixa Corp
  • Developer GlaxoSmithKline
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Non-Hodgkin's lymphoma
  • Discontinued Mantle-cell lymphoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Feb 2014 Withdrawn for Non-Hodgkin's lymphoma (Refractory metastatic disease) in USA and Canada (IV)
  • 07 Aug 2013 GlaxoSmithKline announces intention to withdraw iodine I 131 tositumomab (Barrax®) from the market in USA and Canada on 20 February 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top